Differentiating left ventricular remodelling in aortic stenosis from systemic hypertension and impact of surgical replacement

(2) Abstract

Background Left ventricular (LV) hypertrophy occurs in both aortic stenosis (AS) and systemic hypertension (HTN) in response to wall stress. However, differentiation of hypertrophy due to these two aetiologies is lacking, as well as an understanding of the impact of surgical aortic valve replacement (AVR). The aim was to study the 3-dimensional geometric remodelling pattern in severe AS pre– and post-surgical AVR, and to compare with HTN and healthy controls.

Methods Ninety-one subjects (36 severe AS, 19 HTN and 36 healthy controls) underwent cine cardiac magnetic resonance (CMR). CMR was repeated eight months post-AVR (n=18). Principal component analysis (PCA) was performed on the 3-dimensional meshes reconstructed from 109 CMR myocardial contours of 91 subjects at end-diastole. PCA modes were compared across experimental groups.

Results A unique AS signature was identified by wall thickness linked to a LV left-right axis shift and a decrease in short axis eccentricity. HTN was uniquely linked to increased septal thickness. Combining these three features had good discriminative ability between AS and HTN (AUC=0.792). The LV left-right axis shift was not reversible post-AVR and was predictive of post-operative LV mass regression (R²=0.339, p=0.014). AVR was associated with a reduction in global LV size and correction of short axis eccentricity.

Conclusions Unique remodelling signatures can differentiate the aetiology of LV hypertrophy. LV axis shift is characteristic in AS, is not reversible post AVR, predicts mass regression, and is interpreted to be an adaptive mechanism.

• Download figure
• Open in new tab

Graphical abstract.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by BHF Translational Award (TG/17/3/33406); EU?s Horizon 2020 R&I programme under the Marie Sk?odowska-Curie (764738); National Institute of Health Research (NIHR) Academic Clinical Fellowship (KC); Wellcome/EPSRC Centre for Medical Engineering (WT203148/Z/16/Z); Wellcome Trust Senior Research Fellowship (209450/Z/17/Z) (PL). SGM acknowledges funding support from the Oxford NIHR (National Institute for Health Research) Biomedical Research Centre.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All subjects gave their informed written consent to participate in the study which was approved by Buchkinghamshire, England Research Ethics Committee (Ethics number 07/H0607/66).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes